Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

Russo, Alessandro; Franchina, Tindara; Ricciardi, Giuseppina Rosaria Rita; Battaglia, Alessandra; Scimone, Antonino; Berenato, Rosa; Giordano, Antonio; Adamo, Vincenzo

doi:10.1002/jcp.26609

Cited by 93 publications

(79 citation statements)

References 30 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, a combined leukocyte-CEA score revealed that classified patients into three risk groups showed strong correlation with clinical outcome. Our data are in line to previous reports indicating an unfavorable role of peripheral blood leukocytosis and neutrophilia in the context of inflammation in different malignancies, [12][13][14][15][16][17][18]21 including rectal cancer. 22,23 With regard to NLR, a pooled analysis of retrospective studies indicated a negative predictive impact in rectal cancer.…”

Section: <0001supporting

confidence: 93%

Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO‐04 randomized phase 3 rectal cancer trial

Diefenhardt

Hofheinz

Martin

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Peripheral blood leukocytosis and neutrophilia reflect cancer inflammation and have been proposed as prognostic immunological biomarkers in various malignancies. However, previous studies were limited by their retrospective nature and small patient numbers. Baseline peripheral blood leukocytes, neutrophils, hemoglobin, platelets, lactate dehydrogenase and carcinoembryonic antigen (CEA) were correlated with clinicopathologic characteristics, and clinical outcome in 1236 patients with rectal cancer treated with 5‐FU‐based preoperative chemoradiotherapy (CRT) alone or with oxaliplatin followed by surgery and adjuvant chemotherapy within the CAO/ARO/AIO‐04 randomized phase 3 trial. Multivariable analyses were performed using Cox regression models. After a median follow‐up of 50 months, baseline leukocytosis remained an independent adverse prognostic factor for disease‐free survival (DFS; HR 1.457; 95% CI 1.163–1.825; p = 0.001), distant metastasis (HR 1.696; 95% CI 1.266–2.273; p < 0.001) and overall survival (OS; HR 1.716; 95% CI 1.264–2.329; p = 0.001) in multivariable analysis. Similar significant findings were observed for neutrophilia and high CEA levels. Conversely, treatment‐induced leukopenia correlated with favorable DFS (p = 0.037), distant metastasis (p = 0.028) and OS (p = 0.012). Intriguingly, addition of oxaliplatin to 5‐FU CRT resulted in a significant DFS improvement only in patients with neutrophilia and leukocytosis (p = 0.028 and p = 0.002). Our findings have important clinical implications and provide high‐level evidence on the adverse prognostic role of leukocytes and neutrophils, and the impact of chemotherapy in the context of these biomarkers. These data could help guide patient stratification and should be further validated within prospective studies.

show abstract

Section: <0001supporting

confidence: 93%

Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO‐04 randomized phase 3 rectal cancer trial

Diefenhardt

Hofheinz

Martin

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…However, there was no significant difference between the LIPI 0 and 1 groups, despite the fact that the LIPI 1 group included a greater proportion of poor PS patients than the LIPI 0 group did ( P = 0.001). Russo et al . reported that in patients who received nivolumab or docetaxel, the PFS of the higher dNLR group was not significantly different from that of the lower dNLR group.…”

Section: Discussionmentioning

confidence: 99%

“…In brief, patients with dNLR greater than 3 and LDH higher than the upper limit of normal (ULN) are defined as “Poor (LIPI 2)”, patients with dNLR greater than 3 and LDH lower than ULN or dNLR less than 3 and LDH higher than ULN are defined as “Intermediate (LIPI 1)”, and patients with dNLR less than 3 and LDH lower than ULN are defined as “Good (LIPI 0)” . dNLR and LDH have previously been shown to be useful prognostic factors in many studies . Thus, LIPI with a clear cutoff value is expected to be a useful marker.…”

Section: Introductionmentioning

confidence: 99%

Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Background: The lung immune prognostic index (LIPI) is a marker that combines the derived neutrophil-to-lymphocyte ratio (dNLR) and serum lactate dehydrogenase (LDH) level and is a recently reported prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer (NSCLC). However, there are no reports regarding the prognostic value of LIPI in small cell lung cancer (SCLC). Methods: We retrospectively enrolled 171 patients diagnosed with SCLC and treated at Shinshu University School of Medicine between January 2003 and November 2019. Progression-free survival (PFS) and overall survival (OS) were compared according to LIPI, and we investigated whether LIPI could be a prognostic factor in SCLC using the Kaplan-Meier method and univariate and multivariate Cox models. Results: The median OS of the LIPI 0 group was significantly longer than that of the LIPI 1 plus 2 group (21.0 vs. 11.6 months, P < 0.001). The multivariate analysis associated with OS indicated that LIPI 1 plus 2 was an independent unfavorable prognostic factor in addition to poor performance status (2-3), old age (≥ 75 years) and stage (extensive disease [ED]). However, PFS of the LIPI 0 group was not significantly different from that of the LIPI 1 plus 2 group. In ED-SCLC patients, the median PFS and OS of the LIPI 0 group were significantly longer than those of the LIPI 2 group (6.6 vs. 4.0 months, P = 0.006 and 17.1 vs. 5.9 months, P < 0.001, respectively). Conclusions: We confirmed the prognostic value of LIPI in SCLC, especially ED-SCLC. Key points• Significant findings of the study: The present study is the first to demonstrate that pretreatment lung immune prognostic index is an independent prognostic factor associated with overall survival for small cell lung cancer. • What this study adds: The utility of the lung immune prognostic index as a prognostic factor for small cell lung cancer.

show abstract

“…The following information was extracted from each study: first author's name, publication year, country of origin, number of patients, therapeutic regimen, cancer type, and clinical factors. HRs and 95% CIs were used to combine these data, they were obtained directly from 13 articles when described in text or tables, [14][15][16][17][18][19][20][21][22][23][24][25][26][27] or calculated from available numerical data using methods reported by Tierney et al, [28][29][30] or by emailing the authors. 31 Multivariate data were preferable to univariate data if both were provided; however, univariate data were acceptable if multivariate results were not presented.…”

Section: Data Extractionmentioning

confidence: 99%

“…Suh et al 31 Diem et al 16 Khoja et al 20 Russo et al 24 Overall (I-squared = 80.2%, P = 0.002) 0.0885 1 11.3 NOTE: Weights are from random effects analysis Figure 4 Forest plot of the hazard ratio (HR) of the impact of pretreatment platelet to lymphocyte ratio (PLR) on progression-free survival (PFS) and overall survival (OS). The impact of PLR on (a) PFS and (b) OS.…”

Section: Weight (%)mentioning

confidence: 99%

Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta‐analysis

et al. 2018

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the clinical treatment of multiple cancers. Recent studies revealed the potential prognostic value of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in patients receiving ICIs; however, the results were inconsistent. We conducted a meta‐analysis to identify the prognostic significance of baseline NLR and PLR in cancer patients treated with ICIs.MethodsWe conducted a thorough literature search of PubMed, Embase, and Cochrane databases for studies dealing with the prognostic impact of pretreatment NLR and/or PLR levels in cancer patients treated with ICIs. The clinical outcomes were progression‐free survival (PFS) and overall survival (OS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated, and sensitivity and subgroup analyses were performed to investigate heterogeneity.ResultsSeventeen articles involving 2092 patients were included in the final analysis. The pooled HRs of PFS and OS for NLR were 1.81(95% CI 1.36–2.41) and 2.26 (95% CI 1.68–3.03), respectively, suggesting that patients with higher baseline NLRs had significantly poorer PFS and OS. Similar results were detected in sensitivity and subgroup analyses. However, no significant relevance was found between PLR and clinical endpoints in patients treated with ICIs (HR = 1.14, 95% CI 0.88–1.48 for PFS; HR = 1.35, 95% CI 0.86–2.12 for OS).ConclusionThese results indicate that high pretreatment NLR but not PLR level, as a routinely obtained hematological parameter, is a potential prognostic predictor for poor PFS and OS in cancer patients receiving ICIs.

show abstract

Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

Cited by 93 publications

References 30 publications

Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO‐04 randomized phase 3 rectal cancer trial

Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO‐04 randomized phase 3 rectal cancer trial

Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer

Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta‐analysis

Contact Info

Product

Resources

About